N/A N=28 Increasing Documentation and Disclosure of Sickle Cell Trait Status: An Implementation Science Approach
Sickle Cell Trait
Primary: Acceptability — 11; 8; 11; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=541 eHealth Insomnia Intervention for Adult Survivors of Childhood Cancer
Childhood Cancer · Insomnia · Neurocognitive Impairment
Primary: Change in Insomnia Severity Index (ISI) Scores From Baseline to Post-Intervention (Approximately 10 Weeks After Baseline) — -6.30; -3.91 Score on a scale
N/A N=32 Effects of UC-II, Glucosamine and Curcumin Supplementation on Knee Pain and Inflammation.
Inflammation · Knee Pain Chronic
Primary: Points Change of Pain Evaluation Scale — 1.49; 1.15; 1.15; 1.14 score on a scale — p=0.478
N/A N=5 Evaluation of Lens Rotation in Habitual Wearers of Toric, Soft Contact Lenses
Visual Acuity
Primary: Distance Monocular Visual Acuity (LogMAR) — -0.07; -0.07 logMAR
Phase 4 N=14 Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
Cystic Fibrosis
Primary: Average Rate of Mucociliary Clearance (MCC) Over 60 Minutes — 14.8 percent cleared over 60 minutes — p=0.04
Phase 2 N=95 ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa
Primary: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12 — -2.93; -5.94 AN count — p=>0.999
N/A N=381 Medtronic Signia SDR Product Surveillance Registry
Minimally Invasive Surgical Procedures · Surgical Procedures, Operative
Primary: Incidence of Intraoperative Hemostatic Intervention — 3; 2; 0 Firings
N/A N=30 Maternal Fetal Device Performance Singleton
Pregnancy
Primary: Success Rate Calculated Based on Collection of Fetal Heart Rate Data From Investigational Devices on Subjects Enrolled in Each Gestational Age Group — 85.01; 92.27…
N/A N=104 An RCT of a Telemedicine Intervention for Hypokinetic Dysarthria in PD
Parkinson's Disease
Primary: Change in Speech Intelligibility at 6 Months — 0.25; -4.78 score on a scale — p=0.13
Early Phase 1 N=6 Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC
Bladder Cancer
Primary: Number of Participants With Uptake Spot in 89Zr-girentuximab PET/CT Images — 1; 2; 3 Participants
Phase 2 N=121 A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)
Contraception
Primary: Number of Subjects With Poor Cervical Mucus Scores During Treatment Period — 3; 11 Participants
N/A N=62 Impact of the Inspiratory Cortical Control on the Outcome of the Ventilatory Weaning Test in Patients Intubated in Resuscitation
Respiration Disorder · Respiratory Failure · Weaning Failure
Primary: Magnitude of Inspiratory Premotor Potentials — 1.2; 2.1 µV
Phase 1 N=16 A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
Cough
Primary: Part 1: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Camlipixant — 5811; 4735 Hours*nanograms per milliliter
N/A N=30 Sugars in Cigarettes
Tobacco Use
Primary: Impact of Cigarette Sugar Content on Product Satisfaction. — 4.09; 3.89; 3.92; 4.39 units on a scale
Phase 3 N=381 Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
Irritable Bowel Syndrome With Constipation · Functional Constipation
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs). — 37; 15; 4; 31 Participants